A recent study published in Childhood Obesity highlights critical nutritional considerations for children undergoing treatment with GLP-1 (glucagon-like peptide-1) medications, commonly prescribed for weight management in cases of obesity, prediabetes, or type 2 diabetes. The research revealed that approximately 16.8% of young patients experienced nutritional deficiencies within the first year of treatment, with vitamin D deficiency being the most prevalent, affecting 12.4% of participants.
The study, led by Dr. Justin Ryder and his research team, analyzed national administrative claims data from over 2,000 children aged 10 to 17 who were newly prescribed GLP-1 medications between 2017 and 2022. Findings indicated significant concern regarding the nutritional needs of adolescents undergoing rapid physical and skeletal development. Key nutrients such as vitamin D, iron, and calcium are essential during this growth phase, and deficiencies can have lasting implications for skeletal health and overall development.
A notable gap was identified in nutritional counseling, with only 5% of patients receiving guidance within 30 days of starting GLP-1 therapy and fewer than 25% within six months. Dr. Ryder emphasizes the importance of integrating nutritional support proactively at the initiation of treatment rather than waiting for deficiencies to manifest.
This research underscores the necessity for clinicians, caregivers, and patients to prioritize nutrition during GLP-1 treatment, particularly given its potential to affect appetite and food intake. Early nutritional intervention could mitigate risks associated with deficiencies, ensuring healthier outcomes during a critical developmental stage. However, the study’s reliance on administrative claims data may limit its generalizability, necessitating further investigations to establish comprehensive nutritional protocols alongside pharmacological treatments for pediatric patients.
Source: www.sciencedaily.com
